PharmaNetics' heparin assay trial completed:
This article was originally published in Clinica
PharmaNetics Inc has completed a Phase I field trial of its rapid in vitro assay for monitoring the anticoagulant effects of enoxaparin, Aventis Pharmaceutical's low molecular weight heparin product marketed in the US as Lovenox and elsewhere as Clexane. According to PharmaNetics, the results of the trial show a sufficient correlation with standard laboratory methods to justify proceeding with trials needed for FDA submission. PharmaNetics has optimised the assay's test card formulation and is now validating its manufacturing process.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.